GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aequus Pharmaceuticals Inc (OTCPK:AQSZF) » Definitions » Buyback Yield %

AQSZF (Aequus Pharmaceuticals) Buyback Yield % : 0.00 (As of Apr. 18, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Aequus Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aequus Pharmaceuticals's current buyback yield was 0.00%.


Aequus Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Aequus Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aequus Pharmaceuticals Buyback Yield % Chart

Aequus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -17.39 -16.65 - -

Aequus Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aequus Pharmaceuticals's Buyback Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Aequus Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aequus Pharmaceuticals's Buyback Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aequus Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aequus Pharmaceuticals's Buyback Yield % falls into.


;
;

Aequus Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aequus Pharmaceuticals's Buyback Yield for the fiscal year that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 2.83571492
=0.00%

Aequus Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 1.1141256
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


Aequus Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Aequus Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aequus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
200 Granville Street, Suite 2820, Vancouver, BC, CAN, V6C 1S4
Aequus Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The firm's operating segments are the Commercial platform and Development pipeline. It generates a majority of its revenue from the Commercial platform segment. The Company earns revenues from the sale of dry eye products and by providing promotional services to sell third-party-owned products, namely Tacrolimus IR and Vistitan.

Aequus Pharmaceuticals Headlines

From GuruFocus

Aequus Provides General Update and Reports Record 2021 Financial Results

By GuruFocusNews GuruFocusNews 07-01-2022

Aequus Announces Zimed PF Website Launch

By Marketwired 08-22-2023

Aequus Grants Stock Options

By sperokesalga sperokesalga 04-19-2023

Aequus Provides General Update and Fiscal 2022 Financial Results

By sperokesalga sperokesalga 05-02-2023

Aequus Reports Third Quarter 2022 Financial Highlights

By Value_Insider Value_Insider 11-30-2022